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Abstract
Background: Selection of the optimal initial treatment in patients with major depressive disorder (MDD) in need of
highly specialized care has the potential to benefit treatment outcomes and cost-effectiveness of treatment
strategies. However, to date, there is a paucity of measures that could guide the selection of the initial treatment, in
particular to indicate which patients with MDD are in need of highly specialized care. Recognizing this gap, this
paper reports on the development and psychometric evaluation of the Decision Tool Unipolar Depression (DTUD),
aimed to facilitate the early identification of patients with MDD in need of highly specialized care.
Methods: The DTUD was developed using a mixed-methods approach, consisting of a systematic review and a
concept mapping study. To evaluate the psychometric features of the DTUD, a cross-sectional multicenter study
was conducted. A total of 243 patients with MDD were evaluated with the DTUD. Feasibility was operationalized as
the time required to complete the DTUD and the content clarity of the DTUD. Inter-rater reliability was evaluated
using Krippendorf’s alpha. The Maudsley Staging Method (MSM) and the Dutch Measure for quantification of
Treatment Resistance in Depression (DM-TRD) were administered to assess the convergent validity. A receiver
operator characteristic curve was generated to evaluate the criterion validity and establish the optimal cut-off value.
Results: The mean administration time was 4.49 min (SD = 2.71), and the content of the total DTUD was judged as
clear in 94.7% of the evaluations. Inter-rater reliability values ranged from 0.69 to 0.91. Higher scores on the DTUD
were associated with higher scores on the MSM (rs = 0.47) and DM-TRD (rs = 0.53). Based on the maximum Youden
index (0.494), maximum discrimination was reached at a cut-off score of ≥5 (sensitivity 67%, specificity 83%).
Conclusion: The DTUD demonstrated to be a tool with solid psychometric properties and, therefore, is a promising
measure for the early identification of patients with MDD in need of highly specialized care. Use of the DTUD has
the potential to facilitate the selection and initiation of the optimal initial treatment in patients with MDD, which in
turn may improve the clinical effectiveness and cost-effectiveness of treatment strategies.
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Background
Since delayed initiation of appropriate treatment in pa-
tients with major depressive disorder (MDD) has been
associated with relapse, recurrence and chronicity [1–3],
early initiation of the optimal type and intensity of inter-
vention is considered essential [4]. The stepped care
model of healthcare delivery, according to which many
parts of healthcare systems are organized and sometimes
incentivized to work [5], may however delay the initi-
ation of the optimal type and intensity of intervention.
Within the stepped care approach, patients first receive
the briefest, least intrusive, or least costly intervention,
and only ‘step up’ the treatment pathway in case of
changing treatment needs or insufficient health gains
from initial treatment [6]. Although the stepped care
model of healthcare delivery is considered an appropri-
ate approach in patients who recover with low intensity
treatments [7, 8], the effectiveness and cost-effectiveness
of the stepped care model is questionable in patients
who, identifiably, are in need of high intensity treatment
[6]. Subsequent referral of these patients to highly spe-
cialized mental healthcare (i.e. tertiary mental health-
care) is likely to prolong the treatment course and
compromise clinical and functional outcomes and cost-
effectiveness of treatments. Selection of the optimal ini-
tial treatment in patients with MDD in need of highly
specialized care is therefore warranted, as it can improve
the effectiveness and cost-effectiveness of treatment
paths, but strongly relies on the availability of psycho-
metrically sound instruments to aid clinicians in the
early identification of these patients [4, 9].
Several measures are available to screen for MDD and
assess its severity in clinical and research settings [10–12].
However, to date, there is a paucity of measures that facili-
tate the selection of the optimal initial treatment, in par-
ticular to indicate which patients with MDD are in need
of highly specialized care. Recognizing this gap, in this
paper we report on the development and psychometric
evaluation of the Decision support Tool for the assess-
ment of highly specialized mental healthcare needs of pa-
tients with a Unipolar Depression, or the “Decision Tool
Unipolar Depression” (DTUD) for short. The DTUD is a
10-item clinician-administered instrument to facilitate the
early identification of patients with MDD in need of highly
specialized care. The focus of this paper is on describing
the development of the DTUD and presenting the first re-
sults regarding its feasibility, inter-rater reliability, conver-
gent validity, and criterion validity.
Methods
Definition of terms
As illustrated by the WHO’s Optimal Mix of Services
Pyramid [13], most people with mental health problems
are ideally treated in primary care services. When the
mental health needs require intervention beyond that
which can be provided by primary care services, the pa-
tient should be referred to specialized mental healthcare
services (i.e. secondary mental healthcare) [13]. Special-
ized mental healthcare includes the mental health ser-
vices provided in community mental health centers and
general hospitals [13]. Highly specialized mental health-
care (i.e. tertiary mental healthcare) includes specialized
interventions provided by highly-trained mental health-
care professionals with expertise in a given area to pa-
tients with mental health problems that require
intervention over and above those provided in special-
ized mental healthcare [14, 15]. Given the required level
of staff expertise, management, security, and resources
of highly specialized mental healthcare, those services
are frequently, but not necessarily, affiliated with aca-
demic medical healthcare centers [14].
Decision tool unipolar depression (DTUD) development
Aim of the development of the DTUD was to create a
valid and reliable, yet at the same time short and easy to
score clinician-administered measure to facilitate the
early identification of the subgroup of patients with
MDD who are in need of highly specialized mental
healthcare. The development of the DTUD comprised
the following three phases: (i) identification of indicators
of patients with MDD in need of highly specialized care
through a systematic literature review, (ii) development
of a conceptual framework to inform item generation,
and (iii) development of the measure and evaluation of
face validity and feasibility.
In the first phase of the development of the DTUD, a
systematic literature review was carried out to provide a
scientific foundation for the selection of items included
in the resultant measure [16]. The PubMed and Psy-
cINFO electronic databases were searched for studies
published between January 2000 and January 2015
reporting indicators of patients with MDD in need of
highly specialized care. The search retrieved 7360 refer-
ences, of which 16 met the inclusion criteria. Two re-
viewers determined study eligibility, reviewed study
quality, and performed data abstraction. From the in-
cluded studies, 48 indicators of patients with MDD in
need of highly specialized care were abstracted. For
more details on the systematic review we refer to Van
Krugten et al. [16].
In the second phase of the development of the DTUD,
concept mapping methodology [17] was used to generate
a conceptual framework to guide tool development [18].
In total, 67 MDD experts participated in the subsequent
steps of the concept mapping process. During the first
step of the concept mapping process (i.e. the brain-
storming step), participating experts were asked to re-
view the indicators from the systematic literature review,
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and, when necessary, add additional indicators that
could discriminate MDD patients with and without a
highly specialized care need. In the second step of the
concept mapping process (i.e. the sorting step), partici-
pants individually sorted the resulting indicators from
the brainstorming step into conceptual groupings. The
data from the sorting step were analyzed using nonmet-
ric multidimensional scaling and agglomerative hierarch-
ical cluster analyses, resulting in a ten-cluster concept
map solution. In a consensus meeting, consortium mem-
bers reviewed the concept map and assigned labels to
each of the ten clusters. The ten clusters (i.e. overarch-
ing domains) of indicators of patients with MDD in need
of highly specialized care were assigned the following la-
bels: depression severity, onset and (treatment) course,
comorbid personality disorder, comorbid substance use
disorder, other psychiatric comorbidity, somatic comor-
bidity, maladaptive coping, childhood trauma, social fac-
tors, and psychosocial dysfunction. For more details on
the concept mapping study we refer to Van Krugten et
al. [18].
In the third phase of the development of the DTUD,
members of Decision Tool Unipolar Depression Consor-
tium generated the draft DTUD based on the resulting
overarching domains from the concept mapping study
(phase ii). In a consensus meeting, each of the overarch-
ing domains was operationalized as a dichotomous item.
In order to evaluate the feasibility and face validity of
the DTUD, the draft version of the DTUD was pilot-
tested in a convenience sample of 46 patients aged 18
years or older with a (principal) primary diagnosis of
MDD referred for treatment to a specialized or highly
specialized treatment center in the Netherlands. Partici-
pating clinicians were asked to complete a web-based
survey comprising the draft version of the DTUD, com-
ment on the clarity of content of the DTUD and register
the time needed to complete the DTUD. In a 3-h con-
sensus meeting, consortium members reviewed the pilot
data and made minor revisions to the wording of the
draft version, resulting in the final version of the DTUD.
The resulting DTUD is a 10-item clinician-administered
instrument designed to facilitate the early identification
of individual patients with MDD in need of highly spe-
cialized mental healthcare. Each item has two response
options (“Yes” and “No”). The total score is calculated
by summing the scores of the ten items and ranges from
0 to 10. The abbreviated items of the DTUD are listed
in Table 1. An English translation of the complete
DTUD is presented in Additional file 1.
Study design and population
The aim of the present study was to evaluate the psy-
chometric properties of the DTUD. To that end, a cross-
sectional, observational multicenter study was carried
Table 1 Items, response options and scoring system of the DTUD
Itema Response options Score
1 Severe depression Yes 1
No 0
2 Previous unsuccessful treatment of the index depressive episode in specialized care and a recurrent or chronic course Yes 1
No 0
3 Treatment-interfering comorbid personality disorder Yes 1
No 0
4 Treatment-interfering comorbid substance use disorder Yes 1
No 0
5 Other treatment-interfering psychiatric comorbidity Yes 1
No 0
6 Treatment-interfering somatic comorbidity Yes 1
No 0
7 Treatment-interfering maladaptive coping Yes 1
No 0
8 Severe or longstanding childhood trauma Yes 1
No 0
9 Social factors maintaining the depression Yes 1
No 0
10 Severe psychosocial dysfunctioning Yes 1
No 0
a Item text is abbreviated. An English translation of the complete DTUD is presented in Additional file 1
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out in six psychiatric specialized and highly specialized
outpatient centers in The Netherlands. The Medical Eth-
ical Committee of the Erasmus University Medical Cen-
ter Rotterdam reviewed and approved the study (MEC-
2015-670).
243 randomly selected outpatients referred for treat-
ment of a current episode of MDD to one of the six par-
ticipating sites were evaluated with the DTUD under
routine care conditions. Study inclusion criteria were:
aged 18 years or older and a primary (principal) diagno-
sis of MDD according to Diagnostic and Statistical Man-
ual of Mental Disorders (DSM)-IV criteria. The DSM-IV
axis I diagnosis was determined by the administration of
a Dutch version of the Structured Clinical Interview for
DSM-IV Axis I Disorders (SCID-I) [19] or by a struc-
tured clinical interview using DSM-IV criteria.
Measures
In addition to the DTUD, the following instruments
were administered:
The Maudsley Staging Method (MSM) [20] is a five-
item, clinician-administered instrument designed to
quantify (future) treatment resistant depression (TRD).
The MSM comprises the following three dimensions:
duration, severity and failed treatments in current epi-
sode of depression. The total score ranges from 3 to 15,
and may be categorized into three staging categories:
mild (3–6), moderate (7–10), and severe (11–15).
The Dutch Measure for quantification of Treatment Re-
sistance in Depression (DM-TRD) [21] is an eleven-item,
clinician-administered instrument, and an extension of
the MSM. In addition to the MSM dimensions, the DM-
TRD comprises dimensions for functional impairment,
comorbid anxiety and personality disorders and psycho-
social stressors. The total score ranges from 2 to 27, with
higher values indicating higher levels of TRD.
Procedures
Patients who were referred to one of the six participating
clinics with a primary (principal) diagnosis of MDD were
evaluated with the DTUD. Attending clinicians completed
the DTUD at the end of the diagnostic phase, on the basis
of the diagnostic results. In addition to the DTUD, the
clinician administered the MSM and DM-TRD, recorded
the patients’ basic demographic information (age, sex),
and answered two questions regarding the feasibility of
the DTUD. The participating clinics entered the data in
completely anonymized web-based case report forms as
approved by the institutional review board.
Feasibility was operationalized as the time required to
complete the DTUD, and the content clarity of the
DTUD. Completion time was considered acceptable if the
mean time taken to complete the DTUD was ≤10min.
The clarity of the total DTUD was scored with ‘Yes’ or
‘No’, and was considered acceptable if ≥90% of the infor-
mants evaluated the content of the DTUD as clear. Inter-
rater reliability was assessed in a random subsample of 54
patients using pairs of independent ratings made by two
clinicians present at the same admission interview. Assess-
ment of the criterion validity of the DTUD was conducted
in four out of six participating psychiatric clinics. Since a
reference standard for the determination of need for
highly specialized MDD care was not available, the ex-
perts’ clinical judgement constituted the reference stand-
ard. At each clinic, two clinicians with extensive clinical
experience in the treatment of depressive disorders, inde-
pendently and blinded to the index score (i.e. DTUD),
made a clinical judgment based on the patient’s medical
record as to whether the patient was in need of highly spe-
cialized care (Yes/No). An independent researcher verified
the consistency between the two clinical judgments, and
discrepancies were resolved by a consensus meeting with
the first and second clinician.
Statistical analysis
All analyses were conducted using SPSS (Statistical Package
for the Social Sciences) version 20.0 (IBM SPSS Version 20,
IBM, New York, NY, USA). Statistical significance was in-
ferred at P < 0.05 (two-tailed). Demographic characteristics
and feasibility outcomes were examined using descriptive
statistics. Feasibility outcomes were evaluated according to
the criteria outlined in the procedures section. Inter-rater
reliability was assessed by Krippendorff ’s alpha for individual
items and total DTUD score [22, 23]. Krippendorff ’s alpha
is a conservative reliability estimate for judgments made by
any number of raters, and is adaptable to any level of meas-
urement [24]. For each of the estimated Krippendorff ’s
alpha values, 95% confidence intervals (CIs) were computed
based on 10,000 bootstrap replications. Estimated Krippen-
dorff ’s alpha values were evaluated against the minimum
recommended reliability level of 0.667 [23]. Convergent val-
idity was assessed by Spearman’s correlation coefficients be-
tween total DTUD scale scores and total MSM and DM-
TRD scores. Correlations of 0.10–0.30, 0.30–0.49 and > 0.50
were considered as weak, moderate and strong, respectively
[25]. The DTUD was hypothesized to have a positive correl-
ation with the MSM and DM-TRD. A receiver-operating
characteristic (ROC) curve was generated to assess the cri-
terion validity of the DTUD. In order to determine the opti-
mal cut-off score, a Youden index (J = (sensitivityc +
specificityc) -1) [26] was calculated for a range of cut-off
scores. The cut-off score that corresponded to the highest
Youden index was selected as the optimal cut-off score.
Results
Description of the study population
From November 2015 to April 2016, a total of 243 patients
were studied. Table 2 summarizes the main demographic
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and clinical data of the patients. The mean age of the pa-
tients was 44.22 years (SD = 12.64) and 60.49% (n = 147)
were female. The length of the index depressive episode
was less than twelve months for 44.45%; one year to two
years for 11.52%, and more than two years for 44.03% of
the sample. Using DSM-IV specifiers, the majority of the
patients were diagnosed with moderate (36.63%) or severe
MDD without psychosis (34.98%). The mean total DTUD
score was 3.70 (SD = 2.00). Mean total MSM and DM-TRD
scores were 6.71 (2.42) and 11.30 (3.67), respectively.
Feasibility
The mean administration time was 4.49 min (SD = 2.71),
and the content of the total DTUD was in 94.65% of the
evaluations judged as clear. Two out of 48 clinicians sug-
gested the addition of a mid-point in the set of response
options, such as “maybe” or “don’t know”. Three out of
48 clinicians expressed concern about the clarity of the
items “social factors maintaining the depression” (item
9) and “severe psychosocial dysfunctioning” (item 10),
and suggested the inclusion of examples and descrip-
tions of both items to improve item clarity. Another sug-
gestion included the addition of a statement according
to which grade of diagnostic validity item 3 (comorbid
personality disorder) should be determined - i.e. whether
the item is met in case of a diagnosed personality dis-
order according to a structured interview such as the
Structured Clinical Interview for DSM-IV (SCID) [19]),
or also on the basis of a clinically suspected comorbid
personality disorder, without administration of a formal
structured interview.
Reliability
Inter-rater reliability was determined for 54 participants.
As demonstrated in Table 3, the Krippendorf ’s alpha
value of the total DTUD score was 0.82 (95% CI 0.76–
0.87). The Krippendorff ’s alpha values of the individual
items of the DTUD varied between 0.69 (95% CI 0.52–
Table 2 Demographic and clinical characteristics of study sample
IRR
samplea
Criterion validity samplea Total sample
N 54 132 243
Age, years
Mean (SD) 41.48 (12.15) 44.67 (11.89) 44.22 (12.64)
Range 23–66 22–69 18–78
Sex (n, %)
Male 24 (44.44) 57 (43.18) 96 (39.51)
Female 30 (55.66) 75 (56.82) 147 (60.49)
Duration of current MDD episode (n, %)
Acute (≤12months) 27 (50.00) 56 (42.42) 108 (44.45)
Subacute (13–24 months) 7 (12.96) 13 (9.85) 28 (11.52)
Chronic (> 24months) 20 (37.04) 63 (47.73) 107 (44.03)
Symptom severity of current MDD episode (n, %)
Mild 14 (25.93) 24 (18.18) 48 (19.75)
Moderate 25 (46.30) 47 (35.61) 89 (36.63)
Severe without psychosis 11 (20.37) 49 (37.12) 85 (34.98)
Severe with psychosis 4 (7.41) 12 (9.09) 21 (8.64)
Total DTUD score
Mean (SD) 3.85 (1.85) 3.65 (2.05) 3.70 (2.00)
Range 0.00–8.00 0.00–9.00 0.00–9.00
Total MSM score
Mean (SD) 6.02 (2.16) 6.98 (2.42) 6.71 (2.42)
Range 3.00–13.00 3.00–13.00 3.00–13.00
Total DM-TRD score
Mean (SD) 10.55 (3.13) 11.60 (3.97) 11.30 (3.67)
Range 6.00–23.50 3.00–23.50 3.00–23.50
a Part of total sample
IRR Inter-Rater Reliability, DTUD Decision Tool Unipolar Depression, MSM Maudsley Staging Method, DM-TRD Dutch Measure for quantification of Treatment
Resistance in Depression
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0.83) for comorbid personality disorder and 0.91 (95%
CI 0.77–1.00) for comorbid substance use disorder. No
item was below the minimum recommended reliability
level of 0.667 [23].
Validity
As expected, higher scores on the DTUD were associ-
ated with higher scores on the MSM (rs (241) = 0.47 P <
0.001) and DM-TRD (rs (241) = 0.53, P < 0.001). Figure 1
and Table 4 summarize the operating characteristics of
the DTUD. The area under the curve (AUC) was 0.81
(95% CI 0.73–0.87). Based on the maximum Youden
index of 0.494, maximum discrimination was reached at
a cut-off score of ≥5. This cut-off score demonstrated a
sensitivity of 0.67 (95% CI 0.52–0.79) and a specificity of
0.83 (95% CI 0.73–0.90).
Discussion
This study evaluated the psychometric properties of the
Decision Tool Unipolar Depression (DTUD) in the identi-
fication of patients with MDD in need of highly special-
ized mental healthcare. Overall, the results provide initial
support for the psychometric properties of the DTUD.
The DTUD demonstrated excellent feasibility and ad-
equate inter-rater reliability. The associations with mea-
sures of TRD and health-related quality of life supported
convergent validity. Furthermore, the DTUD demon-
strated satisfactory criterion validity for use in clinical
practice; a cut-off score of ≥5 was found to represent an
optimal cut-off point for identifying patients with MDD in
need of highly specialized care. The results support the
use of the DTUD in busy, routine, outpatient specialized
and highly specialized settings. Both the average comple-
tion time and content clarity of the questionnaire were
within a-priori determined acceptability limits (≤10min
for completion time and ≥ 90% for clarity).
A noteworthy finding is that clinicians tend to disagree
on the presence of a comorbid personality disorder. An
analysis of the provided qualitative feedback regarding this
item suggested that this may be due to the differential
grade of diagnostic validity at which the presence of a co-
morbid personality disorder was determined (i.e. whether
the item is met in case of a diagnosed personality disorder
according to a structured interview, or also on the basis of
a clinically suspected comorbid personality disorder, with-
out the administration of a formal structured interview).
Previous studies have shown that training on how to score
an instrument improves the reliability of a scale [27, 28].
Whether training also improves the reliability of the
DTUD should be studied in future research.
The pattern of correlations between the DTUD and
measures of (future) TRD and health-related quality of life
supported convergent validity. Specifically, the DTUD was
more strongly associated with the DM-TRD than with the
MSM, suggesting that the MSM measures a more dis-
tantly related concept. This is to be expected since the
DM-TRD is an extension of the MSM, additionally includ-
ing items for functional impairment, comorbid anxiety,
personality disorders and psychosocial stressors [21], all of
which are well-known factors associated with unfavour-
able treatment outcome in MDD [29–34]. In addition, the
DTUD showed good discriminative validity relative to the
experts’ clinical judgment of the need for highly special-
ized care (AUC = 0.81). Based on the Youden index, max-
imum discrimination was reached at a cut-off score of ≥5,
with a sensitivity of 67% and a specificity of 83%. A lower
cut-off point (≥4) produced a similar Youden index value
Table 3 Krippendorff’s alpha values of the DTUD (n = 54, 95%
CIs generated by 10,000 bootstrap replications)
Item Krippendorff’s alpha
(95% confidence interval)
1 Severity 0.81 (0.69–0.92)
2 Course 0.82 (0.68–0.92)
3 Comorbid personality disorder 0.69 (0.52–0.83)
4 Comorbid substance use disorder 0.91 (0.77–1.00)
5 Other psychiatric comorbidity 0.78 (0.64–0.90)
6 Somatic comorbidity 0.84 (0.64–0.92)
7 Coping 0.85 (0.74–0.94)
8 Childhood trauma 0.82 (0.70–0.92)
9 Social factors 0.78 (0.64–0.90)
10 Psychosocial functioning 0.73 (0.58–0.85)
Total DTUD score 0.82 (0.76–0.87)
DTUD Decision Tool Unipolar Depression
Fig. 1 ROC curve for the DTUD (area under the curve (AUC) = 0.81)
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with higher sensitivity (86%) but at the cost of a lower spe-
cificity (63%). Given the limited capacity and higher costs
of highly specialized services [13], higher specificity should
be prioritized in order to decrease the rate of false posi-
tives, hence, a score of ≥5 is recommend and should be
tested in future Decision Tool guided studies. For patients
obtaining a DTUD score of 4, an initial evidence-based
treatment in specialized mental healthcare should be com-
bined with systematic monitoring and in case of inad-
equate treatment response, a quick, prioritized referral to
highly specialized care should be strongly considered.
The key strengths of this study are the broad age-
range of the sample, the extensive set of psychometric
properties studied, and the nation-wide representation
of the participating clinical sites (six clinics from across
the country), which adds to the generalizability of the
results. Further, to our knowledge, this is the first study
in which a selection algorithm is developed and vali-
dated that facilitates the early identification of patients
with MDD in need of highly specialized care. The re-
sults should, however, also be viewed in light of some
study limitations. First, the feasibility of the DTUD was
evaluated by completion time and content clarity; fu-
ture studies could also assess the feasibility of the
DTUD with regard to item nonresponse. In the present
study, an analysis of missing values was not possible
since the web-based form was constructed in such a
way that it required completion of all items. Second,
the experts’ clinical judgement constituted the reference
standard for the evaluation of the criterion validity,
which may have introduced subjective error. However,
in the absence of a gold standard test for the identifica-
tion or patients with MDD in need of highly specialized
care, the experts’ clinical judgement was considered the
most adequate and clinically meaningful indication of
highly specialized mental healthcare need. In addition,
to reduce the subjective nature and increase the accur-
acy of the reference standard, the final clinical judg-
ment was based on independent, dual examinations of
comprehensive medical files by clinicians with extensive
clinical experience in the treatment of depressive disor-
ders. Third, the results reported in this paper represent
a first examination of the DTUD psychometric proper-
ties. It was beyond the scope of this study to examine
other issues, such as test-retest reliability, which should
be examined in future studies. Fourth, it should be
noted that the development of assessment tools typic-
ally requires a trade-off between feasibility (i.e. practi-
cality) and validity (i.e. precision). Since the aim was to
develop a simple, routine tool that is quick and easy to
complete, the DTUD was constructed as a simple addi-
tive score of unweighted items. Future research might
examine the relative importance of the individual items,
as well the effect of the use of weighted items on the
feasibility and validity of the DTUD. In addition, al-
though the factors of the DTUD resulted as independ-
ent, distinct indicators of patients with MDD in need of
highly specialized care from the concept mapping study
[18], there might be a potential for reduction of DTUD
items through merging of potentially correlated items.
Since the evaluation of the effect of merging potentially
correlated items on the psychometric properties of the
DTUD would require a new operationalization of items
and subsequent psychometric testing, this evaluation
should be addressed in future studies. Moreover, al-
though the currently recommended cut-off value will
likely generalize to similar psychiatric settings in The
Netherlands, this remains to be validated. Finally, since
the financing and organization of mental healthcare
systems varies internationally [35, 36], future studies
are needed to determine the appropriate cut-off value
for other countries. In this regard, adapting the DTUD
into other languages to test its suitability in similar
groups of patients but in different healthcare systems
may be beneficial to extend its cross-national
robustness.
Conclusions
The results of the present study provide initial support
for the psychometric properties of the DTUD. The
DTUD proves to be a tool with good feasibility, reliabil-
ity and validity and, therefore, is a promising instrument
for the early identification of patients with MDD in need
of highly specialized care. As such, the results of this
study have the potential to facilitate the selection and
initiation of the optimal initial treatment in patients with
MDD, which in turn may improve the clinical effective-
ness and cost-effectiveness of treatment strategies.
Table 4 Operating characteristics of the DTUD with the experts’ clinical judgment constituting the criterion standard
DTUD Scale Score Sensitivity (95% CI) Specificity (95% CI) Youden indexa
≥ 3 0.94 (0.84–0.99) 0.43 (0.32–0.55) 0.373
≥ 4 0.86 (0.74–0.94) 0.63 (0.52–0.73) 0.492
≥ 5 0.67 (0.52–0.79) 0.83 (0.73–0.90) 0.494
≥ 6 0.35 (0.22–0.50) 0.93 (0.85–0.97) 0.279
a Youden index = (sensitivity + specificity) - 1
DTUD Decision Tool Unipolar Depression, CI Confidence Interval
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Additional file
Additional file 1: English translation of the Decision Tool Unipolar
Depression (DTUD). (PDF 177 kb)
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